New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 20, 2014
09:25 EDTABBV, ABBV, ABBV, AMGN, AMGN, AMGN, CELG, CELG, CELG, GILD, GILD, GILD, INCY, INCY, INCY, JNJ, JNJ, JNJ, NVS, NVS, NVS, PCYC, PCYC, PCYC, RHHBY, RHHBY, RHHBYPiper Jaffray's biopharm analyst holds an analyst/industry conference call
Analyst Schimmer, along with Dr. Munib Mundia, CEO of South Nassau Oncology, review CLL and other evolving hematological malignancies with relevant companies PCYC, JNJ, CELG, GILD, INCY, AMGN, ABBV, NVS, RHHBY on an Analyst/Industry conference call to be held on March 21 at 10 am.
News For ABBV;AMGN;CELG;GILD;INCY;JNJ;NVS;PCYC;RHHBY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | all recent news | >>
October 20, 2014
17:26 EDTABBVShire down 1% following termination of merger with AbbVie
Subscribe for More Information
17:17 EDTABBVAbbVie to pay Shire $1.64B break fee
Subscribe for More Information
17:16 EDTABBVAbbVie, Shire announce termination of proposed merger
Subscribe for More Information
17:14 EDTABBVAbbVie, Shire announce termination of proposed merger
15:09 EDTNVSNovartis reports FDA advisory committee recommends approval of secukinumab
Novartis announced the Dermatologic and Ophthalmic Drugs Advisory Committee to the FDA voted unanimously to support the approval of AIN457, or secukinumab, a selective interleukin-17A inhibitor, for the treatment of moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy. A Biologics License Application for secukinumab is currently under FDA review with an anticipated action date in early 2015.
13:26 EDTCELGCelgene I&I franchise boosted by Crohn’s trial data, says William Blair
William Blair said it views the preliminary Phase II efficacy and safety data from mongersen in Crohn’s disease reported by Celgene as encouraging. The firm noted that the 10 mg arm did not achieve significance, but the three data points collectively formed a robust dose-response that William Blair said lends support for the drug's proposed mechanism of action. William Blair believes mongersen complements Celgene’s Inflammation & Immunology portfolio and the firm maintains its Outperform rating on the stock, which is up 4% to $91.65 in afternoon trading.
13:21 EDTCELGCelgene reports Phase II data in Crohn’s Disease to be presented at UEG
Subscribe for More Information
12:37 EDTRHHBYOn The Fly: Midday Wrap
Subscribe for More Information
12:36 EDTJNJOptions with decreasing implied volatility
Subscribe for More Information
09:36 EDTGILDActive equity options trading on open
Subscribe for More Information
08:14 EDTPCYC, JNJPharmacyclics files supplmeental NDA for Imbruvica for macroglobulinemia
Pharmacyclics (PCYC) announced that it has submitted a supplemental New Drug Application to the FDA based on data from a Phase 2 study evaluating the use of IMBRUVICA in patients with Waldenstrom's macroglobulinemia. IMBRUVICA, which received FDA Breakthrough Therapy Designation in February 2013 for patients with WM, is being jointly developed and commercialized by Pharmacyclics and Janssen Biotech (JNJ).
07:47 EDTABBVPfizer less likely to renew Astra pursuit after Shire deal breakdown, FT says
Subscribe for More Information
07:26 EDTNVSFDA Dermatologic & Ophthalmic Drugs Advisory Committee to hold a meeting
Subscribe for More Information
07:19 EDTRHHBY, AMGNIBC Life Sciences to hold a conference
Subscribe for More Information
07:11 EDTABBV, RHHBYAmerican Society for Reproductive Medicine to hold annual meeting
2014 Annual Meeting of ASRM is being held in Honolulu on October 18-22.
07:10 EDTRHHBYAmerican Society of Human Genetics to hold annual meeting
Subscribe for More Information
07:06 EDTRHHBYNewLink announces worldwide license agreement for NLG919 development
Subscribe for More Information
07:04 EDTRHHBYRoche approval would be positive for TESARO, says Jefferies
Subscribe for More Information
06:56 EDTABBVShire reopens acquistion talks with NPS Pharmaceuticals, Cubist, Telegraph says
Subscribe for More Information
October 19, 2014
15:56 EDTAMGNAmgen to aid in production method for Ebola drug ZMapp, Bloomberg says
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use